RT @EBRheum: I should have mentioned ORAL-STANDARD (tofacitinib vs. adalimumab in RA, https://t.co/lKTmsdyE0E) in recent JAKi episode Unli…
132 followers
816 followers
RT @EBRheum: I should have mentioned ORAL-STANDARD (tofacitinib vs. adalimumab in RA, https://t.co/lKTmsdyE0E) in recent JAKi episode Unli…
8,320 followers
RT @EBRheum: I should have mentioned ORAL-STANDARD (tofacitinib vs. adalimumab in RA, https://t.co/lKTmsdyE0E) in recent JAKi episode Unli…
8,806 followers
I should have mentioned ORAL-STANDARD (tofacitinib vs. adalimumab in RA, https://t.co/lKTmsdyE0E) in recent JAKi episode Unlike UPA, TOFA did not demonstrate superiority over ADA. ACR20 61% tofa v. 58% ADA, NS Should not compare trials like this, but use